) recently announced that it has commenced enrollment for a phase
II study on its pipeline candidate OMS824, after reporting
positive data from a phase I study earlier in the month.
We note that OMS824 is the lead compound in Omeros'
phosphodiesterase 10 (PDE10) program. Omeros is developing the
candidate as a PDE10 inhibitor, which is an enzyme expressed in
areas of the brain linked to a wide range of diseases, including
Huntington's disease and schizophrenia, affecting cognition.
The phase II trial will evaluate OMS824's tolerability,
safety, pharmacokinetics and potential interactions with other
related medications in patients suffering from stable
The patients will be administered various doses of OMS824 for
two weeks to assess the effect of OMS824 as a monotherapy and in
combination with other antipsychotic medications. Shares reacted
positively to the news of the initiation of the phase II
We note that, last week, Omeros released new positive data
from a phase I study evaluating the pharmacokinetics of
The encouraging data further support the fact that OMS824 can
achieve superior target engagement with lesser side effects in
comparison to other PDE10 inhibitors in development. Moreover,
OMS824 was well tolerated at the highest multiple-dose level
Meanwhile, we remind investors that Omeros is currently
looking to get its candidate, OMS302, approved in the U.S. and EU
for the treatment of patients undergoing intraocular lens
replacement (ILR) surgery.
Omeros expects to launch OMS302 both in the U.S. and the EU in
the second half of 2014, pending regulatory approval.
We are encouraged by the pipeline progress at Omeros.
Omeros currently carries a Zacks Rank #3 (Hold). Stocks
that currently look attractive include
Biogen Idec Inc.
Gilead Sciences Inc
). All three carry a Zacks Rank #1 (Strong Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
OMEROS CORP (OMER): Free Stock Analysis
To read this article on Zacks.com click here.